FindTrial
Sign In

Ademetionine

DRUG2 trials

Sponsors

MSI Methylation Sciences, Inc., Phenomen Pharma

Conditions

Fatty LiverFatty Liver DiseaseFatty Liver, AlcoholicFatty Liver, NonalcoholicHepatomegalyMajor Depressive DisorderMetabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Nonalcoholic Fatty Liver (NAFL)

Phase 1

Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine
CompletedNCT04623034
MSI Methylation Sciences, Inc.Major Depressive Disorder
Start: 2013-04-17End: 2013-06-08Updated: 2020-11-10

Unknown Phase

Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
RecruitingNCT07068191
Phenomen PharmaFatty Liver, Fatty Liver, Alcoholic, Fatty Liver Disease +5
Start: 2025-06-19End: 2025-08-31Target: 90Updated: 2025-07-23

Related Papers

Pharmacokinetic study of a novel oral formulation of S-adenosylmethionine (MSI-195) in healthy subjects: dose escalation, food effect and comparison to a commercial nutritional supplement product.
2020-12-145 citations